Literature DB >> 1824801

Vaccination for disease.

S Oehen1, H Hengartner, R M Zinkernagel.   

Abstract

Recombinant virus vaccines that express a limited number of epitopes are currently being developed to prevent disease by changing the relative balance between viral spread and the immune response. Some circumstances, however, were found in infections with a noncytopathic virus in which vaccination caused disease; sensitive parameters included the genetic background of the host, the time or dose of infection, and the constituents of the vaccine. Thus, immunopathologic damage by T cells may be an unwanted consequence of vaccination with the new types of peptide or recombinant vaccines that are being investigated for the human immunodeficiency viruses and other pathogens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824801     DOI: 10.1126/science.1824801

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

1.  Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference.

Authors:  W R Beyer; H Miletic; W Ostertag; D von Laer
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 2.  On immunological memory.

Authors:  R M Zinkernagel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

3.  Effects of hydrostatic pressure on a membrane-enveloped virus: high immunogenicity of the pressure-inactivated virus.

Authors:  J L Silva; P Luan; M Glaser; E W Voss; G Weber
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine.

Authors:  Jürgen A Richt; Porntippa Lekcharoensuk; Kelly M Lager; Amy L Vincent; Christina M Loiacono; Bruce H Janke; Wai-Hong Wu; Kyoung-Jin Yoon; Richard J Webby; Alicia Solórzano; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

5.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

Review 6.  Modulation of allergen-specific antibody responses by T-cell-based peptide vaccine(s). Principles and potential.

Authors:  S S Mohapatra
Journal:  Clin Rev Allergy       Date:  1994

7.  Dendritic cells efficiently induce protective antiviral immunity.

Authors:  B Ludewig; S Ehl; U Karrer; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction.

Authors:  M F Bachmann; H Hengartner; R M Zinkernagel
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

9.  Effect of immune priming on Borna disease.

Authors:  A J Lewis; J L Whitton; C G Hatalski; H Weissenböck; W I Lipkin
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  T cell-dependence of Lassa fever pathogenesis.

Authors:  Lukas Flatz; Toni Rieger; Doron Merkler; Andreas Bergthaler; Tommy Regen; Mariann Schedensack; Lukas Bestmann; Admar Verschoor; Mario Kreutzfeldt; Wolfgang Brück; Uwe-Karsten Hanisch; Stephan Günther; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.